Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.

@article{Lancranjan1996SandostatinLA,
  title={Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.},
  author={Ioana Lancranjan and Christian Bruns and Peter Grass and Ph. Jaquet and Jak Jervell and Pat Kendall-Taylor and Steven W. J. Lamberts and Peter Marbach and Hans Orskov and Giorgio Pagani and M L Sheppard and Laura Simionescu},
  journal={Metabolism: clinical and experimental},
  year={1996},
  volume={45 8 Suppl 1},
  pages={67-71}
}
A stable and sustained suppression of growth hormone (GH) secretion was noted in 101 patients treated long term with individual doses (20 and 30 mg in 89 patients, 40 mg in 12 patients) of Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland). Doses of 20 mg and 30 mg at 4-week intervals delivered average octreotide concentrations of 1,348 +/- 483 ng/L and 2,631 +/- 1,026 ng/L, respectively, in steady-state conditions and provided adequate control of patients who had been well controlled… CONTINUE READING